Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ascites × catumaxomab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 3 Ovarian Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Carcinoma 3 Urinary Bladder Neoplasms 2 Fallopian Tube Neoplasms 2 Peritoneal Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms 1 Ascites 1

Interventions

catumaxomab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed

32 enrolled 12 charts

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡